1 00:00:05,920 --> 00:00:10,504 On this episode of Translating Proteomics, co hosts Parag Malik 2 00:00:10,552 --> 00:00:15,192 and Andreas Humer of Nautilus Biotechnology discuss how clinical 3 00:00:15,256 --> 00:00:18,820 researchers can leverage proteomics for drug development. 4 00:00:19,440 --> 00:00:24,824 Some of the themes covered in this episode, proteomics and preclinical 5 00:00:24,872 --> 00:00:30,184 models, how proteomics can drive patient selection and choosing 6 00:00:30,232 --> 00:00:32,888 the right endpoints in clinical trials. 7 00:00:33,064 --> 00:00:37,500 Now, here are your hosts, Parag Malik and Andreas Humer. 8 00:00:38,480 --> 00:00:40,328 Welcome back to Translating Proteomics. 9 00:00:40,424 --> 00:00:43,608 In this episode, we're going to dive into how proteomics can impact 10 00:00:43,664 --> 00:00:44,632 drug development. 11 00:00:44,816 --> 00:00:48,344 In a previous episode, we focused on how proteomics can be 12 00:00:48,352 --> 00:00:50,700 used to discover new drug targets. 13 00:00:51,130 --> 00:00:55,330 Today, we're going to focus much more on how proteomics can improve 14 00:00:55,450 --> 00:00:59,522 the development of preclinical models, how it can be used to recruit 15 00:00:59,586 --> 00:01:04,098 patients, and also how we can help drug developers measure efficacy 16 00:01:04,194 --> 00:01:05,270 more effectively. 17 00:01:06,170 --> 00:01:10,610 Well, let's dive in and chat about starting at the first phase 18 00:01:10,690 --> 00:01:13,430 of drug development, preclinical. 19 00:01:13,850 --> 00:01:17,490 Now, again, we've talked a lot about how proteomics can be used 20 00:01:17,610 --> 00:01:20,626 for identifying targets in the first place. 21 00:01:20,778 --> 00:01:25,154 But in the preclinical stage, we have to think about, we have to 22 00:01:25,162 --> 00:01:27,602 think about the efficacy of the drug, we have to think about 23 00:01:27,626 --> 00:01:32,290 its downstream consequences and we particularly have to try and 24 00:01:32,330 --> 00:01:36,322 understand why is it that this particular drug is working in this 25 00:01:36,346 --> 00:01:38,350 system and this model and not that one. 26 00:01:39,050 --> 00:01:42,706 What have you seen that has really been the highlight for you 27 00:01:42,778 --> 00:01:45,266 of the proteomics used in preclinical research? 28 00:01:45,418 --> 00:01:49,682 So maybe we start with where we've been and maybe then we go where 29 00:01:49,706 --> 00:01:51,986 we will go in the next part of the conversation. 30 00:01:52,018 --> 00:01:58,002 But the first, I would say the last 10 years was really very transformative, 31 00:01:58,066 --> 00:02:02,226 particularly for proteomics, as a lot of tools have been developed 32 00:02:02,258 --> 00:02:06,226 to understand mechanism of action, but also look at off target 33 00:02:06,298 --> 00:02:09,830 effects, meaning when you study a drug and then you're trying 34 00:02:09,870 --> 00:02:13,718 to understand, does it bind to the target of intended target or 35 00:02:13,774 --> 00:02:15,610 does it also do something else? 36 00:02:16,750 --> 00:02:19,654 A lot of work has been done because we can obviously measure 37 00:02:19,702 --> 00:02:22,614 protein and protein interactions in a much more discrete 38 00:02:22,662 --> 00:02:24,806 way in a much larger scale. 39 00:02:24,838 --> 00:02:27,846 That has been possible with typical traditional Western blot 40 00:02:27,878 --> 00:02:29,770 type techniques and immunoassays. 41 00:02:30,270 --> 00:02:33,094 So I think that's a very big step forward. 42 00:02:33,262 --> 00:02:39,252 I would also say that the second phase of that is now emerging 43 00:02:39,316 --> 00:02:43,796 where people are using proteomics to study much more complex 44 00:02:43,908 --> 00:02:48,196 cellular models or even animal models and then I think require another 45 00:02:48,268 --> 00:02:53,364 level of tool set to really understand what's going on when you 46 00:02:53,532 --> 00:02:56,132 apply a drug to a particular organism. 47 00:02:56,276 --> 00:03:02,196 Yeah, I think for me there are really two key areas of research 48 00:03:02,268 --> 00:03:04,006 that I've seen that have been very exciting. 49 00:03:04,188 --> 00:03:08,466 The first is going beyond the genetically determined response markers 50 00:03:08,578 --> 00:03:13,778 and saying, all right, I have a T790M mutation in EGFR and so therefore 51 00:03:13,874 --> 00:03:17,730 my kinase inhibitor isn't going to bind or isn't going to work 52 00:03:17,770 --> 00:03:18,710 as effectively. 53 00:03:19,050 --> 00:03:21,590 But really what happens beyond that mutation? 54 00:03:22,650 --> 00:03:27,666 How does cetuximab overcome things that Gefitinib can't do and 55 00:03:27,818 --> 00:03:31,626 tracing that path to say, all right, well in some cases we aren't 56 00:03:31,658 --> 00:03:35,978 even effectively hitting the protein target, in other cases we're 57 00:03:35,994 --> 00:03:36,810 hitting the protein target. 58 00:03:36,850 --> 00:03:39,514 But there's compensation from downstream pathways. 59 00:03:39,642 --> 00:03:43,882 So things like in the RAS pathway or the MEK pathway compensating, 60 00:03:43,946 --> 00:03:48,510 we see things like CMET overexpression compensating for egfr. 61 00:03:48,850 --> 00:03:52,602 So that's the first layer is just is the drug even able to function? 62 00:03:52,666 --> 00:03:54,310 Is it able to do its job? 63 00:03:54,930 --> 00:03:58,116 The second layer to that is what else is it hitting? 64 00:03:58,148 --> 00:03:59,796 And I think this is what you're talking about. 65 00:03:59,948 --> 00:04:04,916 Most drugs fail not because of lack of efficacy, but because of 66 00:04:05,068 --> 00:04:09,268 off target, cross reactive toxicity concerns. 67 00:04:09,444 --> 00:04:13,044 And so maybe you are hitting the target that you intended, that 68 00:04:13,052 --> 00:04:16,180 you thought you intended, but the consequence of hitting that target 69 00:04:16,220 --> 00:04:20,372 is that three hops down the line you're causing some reaction 70 00:04:20,516 --> 00:04:23,972 that's really dangerous and overlaps with a liver pathway or 71 00:04:23,996 --> 00:04:24,790 something like that. 72 00:04:24,900 --> 00:04:25,266 Correct. 73 00:04:25,298 --> 00:04:29,430 And chemical biology in that sense has made big contributions 74 00:04:30,170 --> 00:04:36,994 in that sense, because as you study much larger number of proteins, 75 00:04:37,042 --> 00:04:40,882 at the same time you can actually see does something else 76 00:04:40,946 --> 00:04:44,242 happen somewhere in the cellular system or the tissue that 77 00:04:44,266 --> 00:04:45,950 I didn't tend to target? 78 00:04:46,730 --> 00:04:50,130 Secondary and tertiary effects are much easier picked up because 79 00:04:50,170 --> 00:04:54,262 we have the ability to, you know, look at much number of proteins 80 00:04:54,406 --> 00:04:57,990 and basically use the discovery power of modern proteomics 81 00:04:58,070 --> 00:05:00,326 to discover these side effects. 82 00:05:00,438 --> 00:05:02,790 And I think historically a lot of these studies were done using 83 00:05:02,830 --> 00:05:06,502 transcriptomic approaches, but from the transcriptomic data you 84 00:05:06,526 --> 00:05:10,886 didn't see that a protein was overexpressed and moved to the membrane 85 00:05:10,918 --> 00:05:12,214 or moved to the nucleus. 86 00:05:12,342 --> 00:05:15,414 You also couldn't tell about protein protein interactions for 87 00:05:15,422 --> 00:05:17,172 instance, or changes in those. 88 00:05:17,366 --> 00:05:21,144 There was a really nice study just this year, 2024, Wasco et al, 89 00:05:21,232 --> 00:05:25,208 where they were looking at the downstream consequences of RAS inhibition. 90 00:05:25,384 --> 00:05:29,980 And I think when we think about these mechanism of action studies, 91 00:05:30,480 --> 00:05:34,888 we really do need to take advantage of am I causing proteomic 92 00:05:34,904 --> 00:05:35,832 rearrangements? 93 00:05:35,976 --> 00:05:38,984 Are those proteomic rearrangements significant or are 94 00:05:38,992 --> 00:05:41,020 they just little responses? 95 00:05:41,360 --> 00:05:43,224 What other pathways are being impacted? 96 00:05:43,272 --> 00:05:46,524 Are we Hitting cell death pathways, cell growth pathways, communication 97 00:05:46,572 --> 00:05:53,196 pathways, and really trying to dive into any given perturbation 98 00:05:53,228 --> 00:05:54,400 that we make in a cell. 99 00:05:55,140 --> 00:05:57,964 The obvious target may not actually be where we want to make 100 00:05:57,972 --> 00:05:58,540 the change. 101 00:05:58,660 --> 00:06:01,132 It may be that when we hit the top of the cascade, we just have 102 00:06:01,156 --> 00:06:04,556 so many downstream consequences that we're headed straight 103 00:06:04,588 --> 00:06:05,628 towards toxicity. 104 00:06:05,724 --> 00:06:08,732 And instead, if we can go three or four hops down in the network, 105 00:06:08,916 --> 00:06:12,044 that will allow us to get the more specific change that we want 106 00:06:12,132 --> 00:06:12,796 to overcome. 107 00:06:12,828 --> 00:06:14,248 A mitogen, for instance. 108 00:06:14,344 --> 00:06:17,160 Yeah, clearly progress in that space. 109 00:06:17,200 --> 00:06:23,112 But I wonder often whether this form of drug discovery is the 110 00:06:23,136 --> 00:06:28,072 most efficient way of discovering new drugs. 111 00:06:28,216 --> 00:06:30,664 And I wonder whether we need to take a very different direction 112 00:06:30,712 --> 00:06:31,540 in the future. 113 00:06:32,320 --> 00:06:35,752 I think, for example, the whole field of spatial omics, I think, 114 00:06:35,776 --> 00:06:39,928 is adding a very interesting aspect to how drugs are distributed. 115 00:06:40,024 --> 00:06:44,682 Maybe there are in hitting the targets they're supposed to be, but 116 00:06:44,706 --> 00:06:48,730 some of them essentially get out of the particular tissue and 117 00:06:48,770 --> 00:06:50,870 then cause problem in other areas. 118 00:06:51,490 --> 00:06:56,074 Well, and I think one other area that we need to really consider 119 00:06:56,162 --> 00:06:58,870 is what model system are we using for what? 120 00:06:59,330 --> 00:07:01,930 Historically, a lot of preclinical studies were done in 121 00:07:01,970 --> 00:07:05,690 2D cell culture, typically monoculture. 122 00:07:05,770 --> 00:07:08,602 So one type of cells, particularly in cancer research or 123 00:07:08,626 --> 00:07:11,914 cardiac research, where we would have just cancer cells in a 124 00:07:11,922 --> 00:07:16,202 dish, what we've seen over time is we've seen an increase in 125 00:07:16,226 --> 00:07:16,842 the complexity. 126 00:07:16,906 --> 00:07:20,586 We've understood that there are interactions between the epithelial 127 00:07:20,618 --> 00:07:25,306 cells, the endothelial cells, other stromal cells that can drive 128 00:07:25,418 --> 00:07:27,514 the responsiveness of a system. 129 00:07:27,682 --> 00:07:31,594 We've seen that secretions from one cell type can influence 130 00:07:31,642 --> 00:07:33,514 the metastatic potential of others. 131 00:07:33,682 --> 00:07:39,172 And so ratcheting up our model systems from monoculture systems 132 00:07:39,236 --> 00:07:46,804 on a plastic dish to even monoculture systems in a more representative 133 00:07:46,852 --> 00:07:47,252 matrix. 134 00:07:47,316 --> 00:07:51,716 So a Jello, for instance, that has a slightly different elastic 135 00:07:51,748 --> 00:07:56,644 modulus can already change the behavior of the cells to ultimately 136 00:07:56,772 --> 00:08:00,084 sets of cells grown as co cultures. 137 00:08:00,212 --> 00:08:03,876 And then we now are seeing a tremendous advance in these organoid 138 00:08:03,908 --> 00:08:07,854 model systems that have many, many different cell types and actual 139 00:08:07,902 --> 00:08:09,370 3D structure to them. 140 00:08:09,830 --> 00:08:10,782 Yeah, I agree with you. 141 00:08:10,806 --> 00:08:15,422 And it's kind of fascinating when you look how these organoids 142 00:08:15,486 --> 00:08:17,650 are essentially created. 143 00:08:17,990 --> 00:08:21,998 In some cases, we don't do anything else, but taking different 144 00:08:22,054 --> 00:08:26,350 cell types and bringing them close to each other so they can communicate. 145 00:08:26,430 --> 00:08:29,166 And just through the communication interaction between 146 00:08:29,238 --> 00:08:32,526 those cell types, they actually start creating, you know, 147 00:08:32,598 --> 00:08:36,462 an organoid of a specific tissue, for example, little brains. 148 00:08:36,606 --> 00:08:40,330 And so I think in this case, the opportunity is to actually take 149 00:08:40,950 --> 00:08:45,262 individual cell types, characterize them you know, you may 150 00:08:45,286 --> 00:08:48,142 have a mutation that you're interested in asking very specific 151 00:08:48,206 --> 00:08:50,254 questions, how it contributes to a disease. 152 00:08:50,382 --> 00:08:53,694 You characterize them on a DNA level, you characterize them on a 153 00:08:53,702 --> 00:08:56,222 proteomic level, and then you bring them together with the rest 154 00:08:56,246 --> 00:08:57,182 of the tissue. 155 00:08:57,326 --> 00:09:01,182 And then you basically have, you know, an engineered system that 156 00:09:01,206 --> 00:09:05,038 allows you now to observe things that you couldn't observe 157 00:09:05,214 --> 00:09:08,990 in the context of a truly complex biological sample. 158 00:09:09,150 --> 00:09:11,982 And I think there's a really important role for proteomics to 159 00:09:12,006 --> 00:09:17,294 play in this, because one can use the proteomics studies to examine 160 00:09:17,422 --> 00:09:20,670 what is the cellular response to perturbation X, how does that 161 00:09:20,710 --> 00:09:23,614 change when the cell is alone, when the cell is on plastic, when 162 00:09:23,622 --> 00:09:28,092 the cell is on a matrigel or in an organoid, when it has its friends 163 00:09:28,116 --> 00:09:29,240 and neighbors around? 164 00:09:29,540 --> 00:09:32,360 And how do those change over time as well? 165 00:09:32,980 --> 00:09:36,652 We've seen some beginning work with proteomics of these different 166 00:09:36,676 --> 00:09:40,348 model systems to assess and validate. 167 00:09:40,444 --> 00:09:43,692 Is this a better model system for this particular question? 168 00:09:43,876 --> 00:09:49,612 The only concern I have when I look at the literature is that I 169 00:09:49,636 --> 00:09:54,808 still think we do not have enough throughput, scalability and 170 00:09:54,864 --> 00:09:55,900 sensitivity. 171 00:09:56,320 --> 00:10:02,344 I think when you have this level of exquisite biological interactions 172 00:10:02,392 --> 00:10:05,380 and there's billions of interactions in these models, right, 173 00:10:05,760 --> 00:10:08,792 we're still stuck at the level of did some of the protein go up 174 00:10:08,816 --> 00:10:12,700 and down, did some of the proteins emerge or disappear? 175 00:10:13,440 --> 00:10:19,842 But we still don't have the scale and the capability to really 176 00:10:19,946 --> 00:10:24,210 understand why, when these cells are communicating, do they 177 00:10:24,250 --> 00:10:25,314 form an organoid? 178 00:10:25,362 --> 00:10:28,594 Or in the case of a dysfunctional cell line? 179 00:10:28,682 --> 00:10:32,626 Why is that dysfunctional cell line now creating a problem within 180 00:10:32,698 --> 00:10:34,790 this, let's say, organoid? 181 00:10:35,210 --> 00:10:38,482 Well, there was a study that our lab did where we were looking 182 00:10:38,586 --> 00:10:41,682 specifically at different types of lung cancer cells. 183 00:10:41,826 --> 00:10:44,434 Some that were more aggressive, some that were more benign, 184 00:10:44,482 --> 00:10:46,350 some that were drug resistant, some that were. 185 00:10:47,410 --> 00:10:52,794 And what we found is that in 2D culture, the aggressive and benign 186 00:10:52,842 --> 00:10:55,870 cells just sort of intermixed completely randomly. 187 00:10:56,450 --> 00:11:00,906 But then when you put them into 3D culture, the more aggressive 188 00:11:00,938 --> 00:11:05,386 cells, they were much happier with the aggressive microenvironments, 189 00:11:05,418 --> 00:11:07,466 the hypoxic microenvironment in the center. 190 00:11:07,578 --> 00:11:12,266 And so even without a drug, you would get an enrichment of aggressive 191 00:11:12,298 --> 00:11:15,356 cells in a harsh microenvironment, forming essentially 192 00:11:15,388 --> 00:11:16,732 an aggressive niche. 193 00:11:16,876 --> 00:11:21,468 And that auto assembly occurred just by microenvironment. 194 00:11:21,564 --> 00:11:24,732 When you looked at the proteome, you saw huge changes in 195 00:11:24,756 --> 00:11:28,348 expression depending upon where you were in that organoid. 196 00:11:28,444 --> 00:11:33,180 And so it was a really clear case to us where the 2D culture while 197 00:11:33,220 --> 00:11:37,100 it was helping us understand in general molecular pathways, it 198 00:11:37,140 --> 00:11:40,132 was completely neglecting the impact from the microenvironment. 199 00:11:40,316 --> 00:11:43,520 So we discussed the preclinical side of drug development 200 00:11:43,980 --> 00:11:48,148 and maybe we think a little bit about the clinical side of drug 201 00:11:48,204 --> 00:11:51,840 development and how proteomics can potentially have an impact there. 202 00:11:52,220 --> 00:11:56,804 I know a lot of customers that I've spoken to often use very sophisticated 203 00:11:56,852 --> 00:12:00,276 proteomics tools in the pre clinical space, but then fade them 204 00:12:00,348 --> 00:12:04,900 out in favor of more simplistic systems like immunoassays. 205 00:12:04,980 --> 00:12:06,000 What's your experience? 206 00:12:06,890 --> 00:12:09,202 I think just thinking about that next phase. 207 00:12:09,266 --> 00:12:12,466 So phase one, phase two clinical trials. 208 00:12:12,578 --> 00:12:17,138 You're getting past your mouse model, you're getting into humans, 209 00:12:17,314 --> 00:12:25,602 and your questions really are about safety, toxicity and dose. 210 00:12:25,746 --> 00:12:27,522 So how much can I give somebody? 211 00:12:27,586 --> 00:12:31,522 What is the minimum effective dose, the maximum tolerated dose? 212 00:12:31,666 --> 00:12:37,502 And on the safety side, on the side effects side, many of these 213 00:12:37,526 --> 00:12:41,198 are gross symptoms like are you having a tummy ache? 214 00:12:41,294 --> 00:12:42,030 Are you? 215 00:12:42,150 --> 00:12:47,534 And so I've seen a lot of hesitation to using more sophisticated 216 00:12:47,582 --> 00:12:49,886 tools as part of those trials. 217 00:12:49,998 --> 00:12:53,810 What I've seen instead is that people have been collecting samples 218 00:12:54,550 --> 00:13:01,310 along the way so that they can do retrospective analyses to understand 219 00:13:01,930 --> 00:13:07,330 the causations of toxicity, dose, response, et cetera. 220 00:13:07,490 --> 00:13:11,874 But I agree with you that I haven't seen people writing explicitly 221 00:13:11,922 --> 00:13:14,178 into the prospective part of their trial. 222 00:13:14,274 --> 00:13:19,266 We're going to do broad scale proteomics specifically for predicting 223 00:13:19,378 --> 00:13:23,826 a response or understanding a response and making a treatment decision 224 00:13:23,978 --> 00:13:25,426 on the basis of it. 225 00:13:25,578 --> 00:13:30,034 And I think that hesitation is because the a priori wants to be 226 00:13:30,042 --> 00:13:34,194 able to have as simple a correlated variable as possible. 227 00:13:34,362 --> 00:13:37,042 If they're going to write it into the trial and they're going 228 00:13:37,066 --> 00:13:39,922 to make a decision based on it, they have to be able to say, 229 00:13:39,946 --> 00:13:41,602 oh, okay, if it's this, I'm going to do this. 230 00:13:41,626 --> 00:13:42,990 If it's that, I'm going to do that. 231 00:13:43,290 --> 00:13:46,962 And so I actually think the challenge here is in part from the 232 00:13:46,986 --> 00:13:50,978 measurement technologies and the cost, ease of use, reproducibility 233 00:13:51,074 --> 00:13:51,770 of them. 234 00:13:51,930 --> 00:13:55,050 But I think it's also on the analysis side of being able to know 235 00:13:55,090 --> 00:13:57,866 exactly what you're going to be looking at and being able to predict 236 00:13:57,898 --> 00:14:00,842 a priori what you think is going to be able to happen. 237 00:14:00,946 --> 00:14:01,322 Yeah. 238 00:14:01,386 --> 00:14:05,642 What I have seen though, that some drug developers developing a 239 00:14:05,666 --> 00:14:09,530 drug, let's say for kidney disease, and then they find out that 240 00:14:09,570 --> 00:14:13,150 during the clinical trial that some people actually develop a favorable 241 00:14:13,490 --> 00:14:18,170 profile, glucose profile of their blood and then they're really 242 00:14:18,210 --> 00:14:23,324 curious, maybe this is the next best diabetes treatment. 243 00:14:23,452 --> 00:14:27,276 And so they come back and say, hey, can someone take all these plasma 244 00:14:27,308 --> 00:14:30,780 samples that we have from the clinical trial and then maybe do 245 00:14:30,820 --> 00:14:35,356 some preclinical study again on finding out why did all of these 246 00:14:35,508 --> 00:14:38,572 patients suddenly show favorable blood profiles in terms 247 00:14:38,596 --> 00:14:39,004 of sugar? 248 00:14:39,052 --> 00:14:42,156 So, but again, that's a retrospective analysis, so that's 249 00:14:42,188 --> 00:14:45,410 not used as part of the prospective design of the trial. 250 00:14:45,540 --> 00:14:48,730 That's not used as part of how we select patients. 251 00:14:49,230 --> 00:14:53,350 It's used post facto to understand variables. 252 00:14:53,430 --> 00:14:56,886 But do you think it's the problem of the powerful proteomics 253 00:14:56,918 --> 00:15:00,710 tools that they basically disclose information that may be 254 00:15:00,750 --> 00:15:04,342 difficult to understand? 255 00:15:04,526 --> 00:15:08,374 Or in the end, when you're trying to prove a drug to explain 256 00:15:08,422 --> 00:15:11,286 why, did you see these changes, which may be completely 257 00:15:11,318 --> 00:15:14,350 innocuous, but there's still changes that can be observed. 258 00:15:14,430 --> 00:15:18,126 Do you think that's one of the major hurdles to use more complex 259 00:15:18,158 --> 00:15:18,734 tools? 260 00:15:18,862 --> 00:15:22,254 I think so, because you are required to report. 261 00:15:22,422 --> 00:15:28,286 So if you write a measurement into a study as something that you're 262 00:15:28,478 --> 00:15:32,530 looking at as a primary or even a secondary endpoint, then you're 263 00:15:32,870 --> 00:15:36,446 required to report out on all of what it finds. 264 00:15:36,638 --> 00:15:40,756 And if you don't know what that is, that can actually potentially 265 00:15:40,788 --> 00:15:44,160 get in the way of your FDA approval process. 266 00:15:44,540 --> 00:15:47,268 And I actually think that's probably wrong. 267 00:15:47,444 --> 00:15:50,884 And this is something we should change in the FDA approval 268 00:15:50,932 --> 00:15:56,212 process is allowing some more permissiveness around secondary variables 269 00:15:56,356 --> 00:16:02,420 that can potentially be part of prospective use. 270 00:16:02,540 --> 00:16:05,800 But maybe in a trial setting. 271 00:16:06,670 --> 00:16:09,014 But today that's very challenging. 272 00:16:09,142 --> 00:16:14,246 Where I have certainly seen it is in places where we are repurposing 273 00:16:14,278 --> 00:16:15,270 therapeutics. 274 00:16:15,430 --> 00:16:17,046 So we already have a long history. 275 00:16:17,118 --> 00:16:20,358 So this is less in phase one, phase two, this is something that's 276 00:16:20,374 --> 00:16:21,490 already made it through. 277 00:16:22,350 --> 00:16:26,742 I think in the NCI match study, they did use large scale sequencing. 278 00:16:26,886 --> 00:16:30,102 So we've seen examples like that where large scale data has been 279 00:16:30,126 --> 00:16:33,792 used for driving patients towards trials and saying, oh, you 280 00:16:33,816 --> 00:16:35,136 should be on this or you should be not. 281 00:16:35,208 --> 00:16:37,220 So it's used as part of patient selection. 282 00:16:37,560 --> 00:16:41,808 So it's actually not explicitly written into the case 283 00:16:41,864 --> 00:16:45,984 report form, but it comes up front to say, oh, I think you'd be 284 00:16:45,992 --> 00:16:47,920 a good match for this trial. 285 00:16:48,080 --> 00:16:48,464 Yeah. 286 00:16:48,512 --> 00:16:54,304 And certainly having a better patient stratification relies on 287 00:16:54,472 --> 00:16:58,100 many, many more data points than the ones you're actually targeting. 288 00:16:58,660 --> 00:17:03,500 And certainly I hope that the application of proteomics tools will 289 00:17:03,540 --> 00:17:07,932 make clinical trials more efficient and ultimately even go 290 00:17:07,956 --> 00:17:10,240 to the point where we have personalized medicine. 291 00:17:11,300 --> 00:17:16,080 Yeah, I think this aspect of who should even be on the trial, 292 00:17:17,060 --> 00:17:20,332 we want folks who have sufficient fitness and there's been 293 00:17:20,516 --> 00:17:21,020 some work. 294 00:17:21,060 --> 00:17:27,222 Erie et al, 20, 21 made sure that a patient would likely be able 295 00:17:27,246 --> 00:17:29,490 to survive through the trial period. 296 00:17:30,670 --> 00:17:36,582 That's a very narrow indication for some of these broad 297 00:17:36,606 --> 00:17:39,958 scale screening or proteomic biomarker associated things. 298 00:17:40,094 --> 00:17:42,582 But ultimately it may be that there are correlated variables that 299 00:17:42,606 --> 00:17:44,502 we're not looking at that right now. 300 00:17:44,526 --> 00:17:45,654 We would say, oh, they're a smoker. 301 00:17:45,702 --> 00:17:48,450 And so we would either rule them in or rule them out. 302 00:17:48,830 --> 00:17:51,894 Maybe we want to be able to go deeper and say, what's their inflammatory 303 00:17:51,942 --> 00:17:52,460 load? 304 00:17:52,590 --> 00:17:55,648 Let's look at in their circulation. 305 00:17:55,744 --> 00:18:00,832 What are we seeing in terms of this set of proteins that are associated 306 00:18:00,896 --> 00:18:04,720 with liver damage and being able to get a little bit more acuity 307 00:18:04,800 --> 00:18:09,312 around the state of the people coming into the trial beyond the 308 00:18:09,496 --> 00:18:10,496 typical measures. 309 00:18:10,608 --> 00:18:14,060 But also what you're arguing for here is that if you had done 310 00:18:15,000 --> 00:18:19,424 in your preclinical studies or used modern proteomics tools with 311 00:18:19,432 --> 00:18:22,246 a broad perspective and already learned that there is maybe 312 00:18:22,278 --> 00:18:25,542 side effects that affect a particular organ, let's call it a 313 00:18:25,566 --> 00:18:26,294 kidney, right. 314 00:18:26,382 --> 00:18:29,782 That when you actually recruit patients, you make sure that there's 315 00:18:29,846 --> 00:18:32,902 nobody with a kidney issue because, you know, that person will 316 00:18:32,926 --> 00:18:37,446 ultimately be counter, you know, counteracting the clinical 317 00:18:37,478 --> 00:18:38,582 trial results, right? 318 00:18:38,686 --> 00:18:39,190 That's right. 319 00:18:39,230 --> 00:18:42,134 So a simple example of this is liver cirrhosis. 320 00:18:42,262 --> 00:18:46,358 So if I'm looking for, if I'm doing a hepatocellular carcinoma 321 00:18:46,374 --> 00:18:51,050 trial, I, I will often ask people, oh, do you drink alcohol? 322 00:18:51,390 --> 00:18:54,790 But it would be great if I could instead. 323 00:18:54,870 --> 00:18:57,654 And people will look at liver enzymes and things like that in a 324 00:18:57,662 --> 00:18:58,742 standard cbc. 325 00:18:58,886 --> 00:19:02,534 But if I could go deeper and understand the extent of the damage 326 00:19:02,582 --> 00:19:05,798 and I could understand if it's present or not, what their history 327 00:19:05,854 --> 00:19:09,382 is, the proteome capturing that lengthy history, I might be 328 00:19:09,406 --> 00:19:12,758 able to do a better job of identifying patients and even just 329 00:19:12,814 --> 00:19:16,758 subtyping them to know, okay, this is what this drug does in an 330 00:19:16,814 --> 00:19:21,720 instance where the, the patients have significant minimal 331 00:19:21,800 --> 00:19:28,620 medial evidence of liver damage or toxicity. 332 00:19:29,600 --> 00:19:33,528 So is there a particular example where proteomics tools are 333 00:19:33,584 --> 00:19:39,432 exquisitely used to understand what drives a disease and you are 334 00:19:39,456 --> 00:19:42,136 unable to get that same information from, let's say, a DNA 335 00:19:42,168 --> 00:19:43,300 or RNA level? 336 00:19:44,330 --> 00:19:48,178 Yeah, I think actually there's really elegant work from Paul Michel's 337 00:19:48,194 --> 00:19:48,466 lab. 338 00:19:48,538 --> 00:19:52,722 He's now at Stanford along with some of the Tim Clausey and 339 00:19:52,746 --> 00:19:54,178 others at UCLA. 340 00:19:54,354 --> 00:19:59,442 Looking at EGFR V3 in a variety of conditions, it's often 341 00:19:59,546 --> 00:20:04,226 expected that overexpression of EGFR will imply responsiveness 342 00:20:04,258 --> 00:20:06,146 to EGFR targeted therapies. 343 00:20:06,338 --> 00:20:10,804 However, if, for instance, you have a mutation or a heterozygous 344 00:20:10,852 --> 00:20:15,680 mutation, the transcript is unable to resolve that. 345 00:20:15,980 --> 00:20:20,320 And then even often protein staining can be complicated because 346 00:20:21,020 --> 00:20:26,900 you need a protein antibody that targets just the insert region 347 00:20:27,020 --> 00:20:32,548 and is sensitive enough to tolerate having a heterozygous population. 348 00:20:32,724 --> 00:20:37,160 It's even more interesting in glioblastoma because it's been shown, 349 00:20:37,760 --> 00:20:40,900 again, great work by Paul Michel's group, that you can have 350 00:20:41,520 --> 00:20:46,072 a extra chromosomal segment that is transferred from cell to 351 00:20:46,096 --> 00:20:46,856 cell to cell. 352 00:20:46,968 --> 00:20:50,120 So it's not actually even in the genome, it's just leading to 353 00:20:50,160 --> 00:20:54,824 expression of a protein in a non within the genome manner. 354 00:20:54,952 --> 00:20:58,504 And it can be in a small subset of cells or it can explode 355 00:20:58,552 --> 00:20:59,768 and be in many cells. 356 00:20:59,864 --> 00:21:04,090 And the proteomic analysis of that helps us look at what is the 357 00:21:04,130 --> 00:21:09,818 actual expression of the v3 form that these therapies are going 358 00:21:09,874 --> 00:21:10,522 after. 359 00:21:10,706 --> 00:21:14,650 So it's really a critical example where the therapeutic is 360 00:21:14,690 --> 00:21:17,834 completely ineffective without having the right form of the protein 361 00:21:17,882 --> 00:21:18,522 present. 362 00:21:18,706 --> 00:21:22,426 And you can't find the form of the protein by looking at anything 363 00:21:22,458 --> 00:21:23,790 other than the protein. 364 00:21:24,210 --> 00:21:28,170 So does it also mean that maybe some of the work we do right 365 00:21:28,210 --> 00:21:32,592 now, the overemphasis on application of genomic tools in that 366 00:21:32,616 --> 00:21:36,220 space maybe is the wrong thing to do? 367 00:21:39,640 --> 00:21:43,104 I need to be a little careful here and not say that no one should 368 00:21:43,112 --> 00:21:44,432 do genomics ever. 369 00:21:44,616 --> 00:21:45,728 No, that's not what I'm saying. 370 00:21:45,784 --> 00:21:46,384 That's not what you're saying. 371 00:21:46,392 --> 00:21:46,656 Okay. 372 00:21:46,688 --> 00:21:47,340 All right. 373 00:21:47,800 --> 00:21:51,104 I think the reality is that different processes are regulated 374 00:21:51,152 --> 00:21:52,256 at different layers. 375 00:21:52,448 --> 00:21:56,112 And so oftentimes we've been doing a lot of genomic analysis because 376 00:21:56,136 --> 00:22:00,376 it's accessible and we've seen individual mutations, we've seen 377 00:22:00,448 --> 00:22:04,664 changes in chromosomal duplications, et cetera. 378 00:22:04,712 --> 00:22:09,688 Copy number variation has had associations with phenotypes. 379 00:22:09,864 --> 00:22:13,944 Now where that's broken down is again, in heterozygous populations, 380 00:22:13,992 --> 00:22:15,240 this can break down. 381 00:22:15,360 --> 00:22:17,912 It can also break down when there are other processes that are 382 00:22:17,936 --> 00:22:22,040 driven at the proteomic scale that are simply not measurable. 383 00:22:22,120 --> 00:22:26,320 So changes in degradation pathways, for instance, those are 384 00:22:26,440 --> 00:22:29,540 basically invisible to the genome and transcriptome. 385 00:22:29,880 --> 00:22:36,096 And yet HIF1 alpha hypoxia, inducible factor, known factor in 386 00:22:36,248 --> 00:22:40,260 hypoxic response, known factor in driving aggressivity in cancer. 387 00:22:40,600 --> 00:22:43,456 Very hard to study any other way than by looking at the protein 388 00:22:43,488 --> 00:22:48,816 because the transcript doesn't obey the behavior of if I experience 389 00:22:48,888 --> 00:22:50,480 a hypoxic stress response. 390 00:22:50,640 --> 00:22:54,404 So I do think that there is tremendous value in having the genome 391 00:22:54,452 --> 00:22:58,692 data, but I think we just have to be really cognizant of the fact 392 00:22:58,716 --> 00:23:02,036 that it's incomplete, it doesn't fully capture the dynamics 393 00:23:02,068 --> 00:23:03,716 of what's happening in the cell. 394 00:23:03,908 --> 00:23:09,124 And even if we take it over time, we're seeing evolution in the 395 00:23:09,132 --> 00:23:11,796 genome, but we're not necessarily getting the complexity 396 00:23:11,828 --> 00:23:15,972 of the cell states or the cell state composition of a tumor, which 397 00:23:16,076 --> 00:23:17,406 are hugely dynamic. 398 00:23:17,548 --> 00:23:21,786 So I mean, the takeaway would be not to solely rely on DNA or RNA 399 00:23:21,818 --> 00:23:24,826 tools, although they're so cheap and accessible that probably 400 00:23:24,858 --> 00:23:26,554 you would do the measurement anyway. 401 00:23:26,682 --> 00:23:30,554 But then don't stop there and continue to measure things on the 402 00:23:30,562 --> 00:23:35,306 proteomic level to make sure that you haven't overlooked particular 403 00:23:35,378 --> 00:23:36,026 mechanism. 404 00:23:36,138 --> 00:23:39,162 Yeah, I think ultimately what you'd like to get to the point is 405 00:23:39,186 --> 00:23:42,634 where we understand where the control points for different processes 406 00:23:42,682 --> 00:23:45,750 live and then maybe we don't need to measure quite everything, 407 00:23:45,790 --> 00:23:47,766 but we need to measure those control points. 408 00:23:47,918 --> 00:23:50,006 We're just not at that place right now. 409 00:23:50,158 --> 00:23:53,414 So it's incumbent upon us to measure as much as possible so that 410 00:23:53,422 --> 00:23:55,222 we can learn where those control points are. 411 00:23:55,326 --> 00:23:59,846 So if you had to guess how many diseases or how many mechanisms 412 00:23:59,878 --> 00:24:03,670 are dependent on genomic regulation versus proteomic level 413 00:24:03,790 --> 00:24:05,930 regulation, Any wild guess? 414 00:24:07,230 --> 00:24:12,566 Well, I don't think we need to make a wild guess because we generally 415 00:24:12,598 --> 00:24:20,896 have a sense of, of which inborn errors lead to downstream 416 00:24:20,928 --> 00:24:21,792 consequences. 417 00:24:21,936 --> 00:24:25,552 Genetically associated diseases that are one to one and 418 00:24:25,576 --> 00:24:26,720 don't have environmental factors. 419 00:24:26,800 --> 00:24:29,712 And I think it's something like 2% of diseases fall into that 420 00:24:29,736 --> 00:24:30,512 category. 421 00:24:30,656 --> 00:24:31,024 Yeah. 422 00:24:31,072 --> 00:24:32,768 So it's very little, it's very low. 423 00:24:32,824 --> 00:24:33,460 Yeah. 424 00:24:34,200 --> 00:24:37,168 So far we focused a lot on preclinical studies and phase one, 425 00:24:37,224 --> 00:24:38,060 phase two. 426 00:24:38,920 --> 00:24:41,424 One of the things that comes up when we start thinking about phase 427 00:24:41,472 --> 00:24:44,686 three is we're really talking about efficacy and we're talking 428 00:24:44,718 --> 00:24:47,450 about efficacy relative to standard of care. 429 00:24:48,310 --> 00:24:51,390 There it becomes particularly important to understand are we looking 430 00:24:51,430 --> 00:24:53,370 at the relevant thing? 431 00:24:53,670 --> 00:24:57,838 And we have examples where we aren't looking at the relevant thing. 432 00:24:57,894 --> 00:25:02,126 Proteins themselves are not always the relevant thing In Alzheimer's 433 00:25:02,158 --> 00:25:02,686 disease. 434 00:25:02,798 --> 00:25:08,224 Amyloid plaques are clearly a component of the disease. 435 00:25:08,422 --> 00:25:12,892 However, there was a series of studies, clinical trial results, 436 00:25:13,076 --> 00:25:17,292 Sims et al, Vandyke et al, that they were looking at the prevalence 437 00:25:17,356 --> 00:25:22,028 of A beta plaques and or the disappearance of A beta plaques on 438 00:25:22,084 --> 00:25:25,468 different drugs, or different drugs impact on them. 439 00:25:25,604 --> 00:25:32,396 And it wasn't super predictive of either neurological burden or 440 00:25:32,468 --> 00:25:36,782 of effectiveness of the therapy in improving the the state 441 00:25:36,806 --> 00:25:37,806 of the disease. 442 00:25:37,998 --> 00:25:44,030 So while proteins are clearly important and drivers, this question 443 00:25:44,150 --> 00:25:49,678 of what should we look at understanding where we should look, 444 00:25:49,734 --> 00:25:52,494 when we should look, and what we should look should be our ultimate 445 00:25:52,542 --> 00:25:53,054 goal. 446 00:25:53,182 --> 00:25:53,582 Yeah. 447 00:25:53,646 --> 00:25:56,478 I mean, in the case of Alzheimer's, it's a very complex 448 00:25:56,574 --> 00:26:00,622 network of proteins that ultimately lead to the cognitive 449 00:26:00,686 --> 00:26:01,410 decline. 450 00:26:02,580 --> 00:26:08,476 And so, yeah, it was part of the big revelation the last several 451 00:26:08,548 --> 00:26:12,780 years where biomarkers were discovered that actually are tracing, 452 00:26:12,860 --> 00:26:16,012 tracking with the progression of the disease and ultimately the 453 00:26:16,036 --> 00:26:16,844 cognitive decline. 454 00:26:16,892 --> 00:26:21,244 And there was certainly a lot of work needed and several proteins 455 00:26:21,292 --> 00:26:26,156 had to be sort of discarded as good biomarkers. 456 00:26:26,348 --> 00:26:29,698 For example, neurofilaments themselves are not good biomarkers 457 00:26:29,714 --> 00:26:32,082 because they don't correlate with the disease, but they're certainly 458 00:26:32,146 --> 00:26:38,210 changing a lot with neurodegeneration and similar other 459 00:26:38,250 --> 00:26:39,470 proteins as well. 460 00:26:40,170 --> 00:26:44,354 Interesting, though, is that if you think through, for example, 461 00:26:44,402 --> 00:26:48,306 in Alzheimer's disease, finding the right protein is definitely 462 00:26:48,338 --> 00:26:52,898 a challenge because in some patients you actually may have mutation 463 00:26:53,074 --> 00:26:57,250 in some of the proteins involved and certainly then they 464 00:26:57,290 --> 00:27:02,562 become the focus of a drug target, whereas in others, where 465 00:27:02,586 --> 00:27:07,586 there's more sporadic disease, in this case, you probably don't 466 00:27:07,618 --> 00:27:09,250 have to look at particular proteins. 467 00:27:09,330 --> 00:27:09,810 Right. 468 00:27:09,930 --> 00:27:10,370 Yeah. 469 00:27:10,450 --> 00:27:15,410 Well, I think part of it is understanding there are aspects that 470 00:27:15,450 --> 00:27:20,740 may be mechanistic and drivers early on in the disease and then 471 00:27:20,780 --> 00:27:23,332 later in the disease, they may not be as predictive. 472 00:27:23,476 --> 00:27:27,732 So one of the questions we have when designing a trial is what 473 00:27:27,756 --> 00:27:31,204 are our primary endpoints, what are our secondary endpoints, 474 00:27:31,252 --> 00:27:34,196 and what are things that we're collecting along the way? 475 00:27:34,348 --> 00:27:38,564 And we've seen examples of therapeutics that have been approved 476 00:27:38,692 --> 00:27:42,196 based on primary endpoints that didn't actually improve patient 477 00:27:42,228 --> 00:27:43,156 welfare. 478 00:27:43,348 --> 00:27:46,052 And so this is a place where I think we have to be a little bit 479 00:27:46,076 --> 00:27:48,946 careful, is making sure that, again, we're measuring. 480 00:27:49,058 --> 00:27:52,850 It may not always be possible to measure cognitive decline. 481 00:27:53,010 --> 00:27:54,962 It's a very narrow. 482 00:27:55,106 --> 00:27:56,578 It's hard to measure. 483 00:27:56,754 --> 00:27:59,170 So having a molecular surrogate is really helpful. 484 00:27:59,330 --> 00:28:02,066 But are we measuring the right molecular surrogate? 485 00:28:02,178 --> 00:28:05,042 And in retrospect, many clinical trials probably would have 486 00:28:05,146 --> 00:28:09,350 given better results if the right endpoint would have been picked 487 00:28:10,090 --> 00:28:10,898 from the start. 488 00:28:10,954 --> 00:28:11,362 Right. 489 00:28:11,466 --> 00:28:13,364 And that's certainly a very difficult task. 490 00:28:13,482 --> 00:28:14,260 Yeah. 491 00:28:15,000 --> 00:28:19,100 I think the other thing that we really have to be aware of is 492 00:28:19,480 --> 00:28:25,344 when clinical trials fail, either phase one, phase two, phase 493 00:28:25,392 --> 00:28:28,860 three, are we doing enough to bring that data together? 494 00:28:29,240 --> 00:28:33,552 So many drugs we know fail because of toxicity, some fail because 495 00:28:33,576 --> 00:28:34,864 of lack of efficacy. 496 00:28:34,992 --> 00:28:38,384 But when they fail, what's done with that data? 497 00:28:38,552 --> 00:28:41,848 Both all the data that was collected to that point and the data 498 00:28:41,904 --> 00:28:46,312 from that specific trial, can we use our proteomics analysis to 499 00:28:46,336 --> 00:28:50,360 go back and say, oh, you know, people who in general have failed, 500 00:28:50,520 --> 00:28:56,632 they failed because of this panel of cardiac enzymes going up 501 00:28:56,656 --> 00:28:57,304 in the blood. 502 00:28:57,432 --> 00:28:57,928 Yeah. 503 00:28:58,024 --> 00:29:01,272 And so maybe there's a big opportunity in the future to use 504 00:29:01,456 --> 00:29:07,180 modern AI tools to sort of mine for clues that we have overlooked 505 00:29:07,770 --> 00:29:14,002 and find maybe there is indication that or maybe you can 506 00:29:14,026 --> 00:29:18,390 learn something from these trials that actually were unsuccessful. 507 00:29:20,650 --> 00:29:23,666 Thanks so much for joining us today on Translating Proteomics. 508 00:29:23,778 --> 00:29:28,146 Today we talked about how proteomics is impacting all throughout 509 00:29:28,178 --> 00:29:31,186 the drug development process, and we particularly talked about 510 00:29:31,258 --> 00:29:35,326 its impact on preclinical models, how it can help us recruit 511 00:29:35,358 --> 00:29:39,950 patients, and how proteomics in general can help drug developers 512 00:29:40,030 --> 00:29:42,290 measure efficacy and learn from failures. 513 00:29:43,510 --> 00:29:46,910 We'd love to hear from you if you have stories or experiences where 514 00:29:46,950 --> 00:29:49,646 you've used proteomics as part of your drug development efforts, 515 00:29:49,758 --> 00:29:53,742 or you have questions about ways that proteomics might be part 516 00:29:53,766 --> 00:29:57,246 of the process, or you have frustrations said, wow, my proteomics 517 00:29:57,278 --> 00:29:58,868 was great here and terrible there. 518 00:29:58,974 --> 00:30:00,312 We'd love to hear from you. 519 00:30:00,416 --> 00:30:01,780 Hit us back in the comments. 520 00:30:04,400 --> 00:30:08,168 We hope you enjoyed the Translating Proteomics podcast brought 521 00:30:08,184 --> 00:30:10,568 to you by Nautilus Biotechnology. 522 00:30:10,744 --> 00:30:14,840 To contact us or for further information, please email Translating 523 00:30:14,920 --> 00:30:16,920 Proteomics at Nautilus Bio.